Stock Comparison
ABT vs DXCM
Abbott Laboratories vs Dexcom Inc
The Verdict
DXCM takes this one.
Head-to-Head
Market Cap
P/E Ratio
Profit Margin
Return on Equity
Debt-to-Equity
Overall Risk
DVR Score
The Deep Dive
Abbott Laboratories remains a highly stable and diversified global healthcare leader, further solidifying its position with the recent $23 billion Exact Sciences acquisition which boosts its cancer diagnostics segment and is expected to accelerate 2026 revenue growth. While the company demonstrates robust financial health, strong competitive moats (e.g., FreeStyle Libre), and strategic capital all...
Full ABT AnalysisDexcom maintains its strong position as a market leader in the Continuous Glucose Monitoring (CGM) sector, driven by the ongoing global rollout of G7 and promising initial traction for Stelo in the Type 2 non-insulin market. The company showcases a clear strategic vision for significant Total Addressable Market (TAM) expansion, supported by robust R&D and regulatory expertise, solid financial heal...
Full DXCM AnalysisWant More Comparisons?
Run any stock through our deep value analyzer.
Analyze Any Stock →Not Financial Advice
This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.